The application of multipotent mesenchymal stromal cells with overexpression of the vegf 165 gene to correct coronary insufficiency

A new approach to the treatment of patients with coronary heart disease is based on the use of either pharmacological drugs, mainly to eliminate the symptoms of the disease, as well as the prevention of" terrible " complications (myocardial infarction), or a combination of pharmacological and surgical methods (stenting and/or coronary artery bypass grafting). However, the use of surgical methods is not always possible (there are a number of absolute contraindications to coronary bypass surgery and / or the use of interventional technologies) or is limited, for example, by the small diameter of the main coronary arteries or their angulation, and vascular stenting is accompanied by a high risk of thrombosis (with multivessel lesions) and the formation of restenosis. The simultaneous use of MMSCs transfected with VEGF-165, accompanied by synergistic effects, makes it possible to link future prospects for therapeutic angiogenesis with the use of stem cells transfected with growth factor genes and the factors themselves that enhance the effect of gene-cell constructs.